Skip to main content

Advertisement

Fig. 6 | Journal of Neuroinflammation

Fig. 6

From: A novel antagonist of p75NTR reduces peripheral expansion and CNS trafficking of pro-inflammatory monocytes and spares function after traumatic brain injury

Fig. 6

EVT901 treatment reduced CD45 + CCR2+ double-positive monocytes in the injured brain in C57Bl/6 WT mice at 7 days after TBI. a Brain tissue sections were immuno-stained with CCR2 Ab and CD45 Ab. b TBI increased the CD45 + CCR2+ double-positive signal in the injured area, while EVT901 treatment abrogated this effect. ANOVA revealed a significant main effect of condition (F 2,6 = 14.50, p = 0.005, η 2 = 0.83, power = 0.96) and section (F 4,24 = 5.86, p = 0.002, η 2 = 0.49, power = 0.96). Tukey’s post hoc test showed a significant difference between uninjured and TBI-vehicle (p = 0.004). c Tissue area was significantly reduced by TBI, and this effect was abrogated by EVT901. One-way ANOVA showed a main effect of condition (F 2,6 = 14.06, p = 0.003, η 2 = 0.82, power = 0.96). Tukey’s post hoc tests showed that TBI-vehilce, but not EVT901, was different from uninjured control (p < 0.004). Scale bar in A = 1000 μm (left) and 100 μm (right). (n = 3 for UN and n = 5 for TBI groups)

Back to article page